$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000082787118000005 Filed on May 10, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$46.63M	$76.79M
YoY Change	-39.28%	159.51%
Cost Of Revenue	$7.223M	$10.77M
YoY Change	-32.9%	-26.21%
Gross Profit	$34.82M	$66.03M
YoY Change	-47.27%	340.13%
Gross Profit Margin	74.68%	85.98%
Selling, General & Admin	$15.19M	$18.58M
YoY Change	-18.22%	53.18%
% of Gross Profit	43.64%	28.14%
Research & Development	$17.32M	$7.525M
YoY Change	130.17%	36.3%
% of Gross Profit	49.74%	11.4%
Depreciation & Amortization	$341.0K	$196.0K
YoY Change	73.98%	40.0%
% of Gross Profit	0.98%	0.3%
Operating Expenses	$44.32M	$44.10M
YoY Change	0.51%	44.64%
Operating Profit	$2.305M	$32.70M
YoY Change	-92.95%	-3745.04%
Interest Expense	$675.0K	$27.00K
YoY Change	2400.0%
% of Operating Profit	29.28%	0.08%
Other Income/Expense, Net	-$648.0K	-$24.00K
YoY Change	2600.0%	-220.0%
Pretax Income	$1.657M	$32.67M
YoY Change	-94.93%	-3825.43%
Income Tax	-$959.0K	$9.748M
% Of Pretax Income	-57.88%	29.84%
Net Earnings	$2.616M	$22.92M
YoY Change	-88.59%	-2658.48%
Net Earnings / Revenue	5.61%	29.85%
Basic Earnings Per Share	$0.18	$1.50
Diluted Earnings Per Share	$0.17	$1.42
COMMON SHARES
Basic Shares Outstanding	14.82M shares	15.26M shares
Diluted Shares Outstanding	15.48M shares	16.17M shares

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$95.70M	$27.70M
YoY Change	245.49%	-64.62%
Cash & Equivalents	$95.67M	$27.71M
Short-Term Investments
Other Short-Term Assets	$580.0K	$1.215M
YoY Change	-52.26%	486.96%
Inventory	$6.141M	$3.015M
Prepaid Expenses
Receivables	$53.43M	$84.74M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$168.8M	$123.6M
YoY Change	36.62%	7.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.498M	$3.796M
YoY Change	71.18%	32.31%
Goodwill	$39.74M	$39.74M
YoY Change	0.0%
Intangibles	$22.65M	$32.66M
YoY Change	-30.64%	193.81%
Long-Term Investments
YoY Change
Other Assets	$106.0K	$618.0K
YoY Change	-82.85%	557.45%
Total Long-Term Assets	$80.48M	$101.2M
YoY Change	-20.52%	619.14%
TOTAL ASSETS
Total Short-Term Assets	$168.8M	$123.6M
Total Long-Term Assets	$80.48M	$101.2M
Total Assets	$249.3M	$224.8M
YoY Change	10.89%	74.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.353M	$19.03M
YoY Change	-50.84%	84.82%
Accrued Expenses	$13.10M	$15.40M
YoY Change	-14.92%	-21.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.250M
YoY Change
Total Short-Term Liabilities	$28.76M	$35.44M
YoY Change	-18.84%	14.8%
LONG-TERM LIABILITIES
Long-Term Debt	$41.62M	$0.00
YoY Change
Other Long-Term Liabilities	$700.0K	$22.60M
YoY Change	-96.9%
Total Long-Term Liabilities	$41.62M	$22.60M
YoY Change	84.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.76M	$35.44M
Total Long-Term Liabilities	$41.62M	$22.60M
Total Liabilities	$70.38M	$58.00M
YoY Change	21.35%	59.34%
SHAREHOLDERS EQUITY
Retained Earnings	$28.90M	-$2.735M
YoY Change	-1156.67%	-97.47%
Common Stock	$16.00K	$16.00K
YoY Change	0.0%	6.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$87.80M	$50.66M
YoY Change	73.32%
Treasury Stock Shares	1.365M shares	756.0K shares
Shareholders Equity	$178.2M	$166.8M
YoY Change
Total Liabilities & Shareholders Equity	$249.3M	$224.8M
YoY Change	10.89%	74.68%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	$2.616M	$22.92M
YoY Change	-88.59%	-2658.48%
Depreciation, Depletion And Amortization	$341.0K	$196.0K
YoY Change	73.98%	40.0%
Cash From Operating Activities	$4.921M	-$12.44M
YoY Change	-139.57%	-500.13%
INVESTING ACTIVITIES
Capital Expenditures	$19.00K	$676.0K
YoY Change	-97.19%	-15.92%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$19.00K	-$676.0K
YoY Change	-97.19%	-82.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$7.003M	$13.65M
YoY Change	-48.71%
Debt Paid & Issued, Net	$0.00
YoY Change
Cash From Financing Activities	-$23.89M	-$12.00M
YoY Change	99.11%
NET CHANGE
Cash From Operating Activities	$4.921M	-$12.44M
Cash From Investing Activities	-$19.00K	-$676.0K
Cash From Financing Activities	-$23.89M	-$12.00M
Net Change In Cash	-$18.99M	-$25.11M
YoY Change	-24.38%	3054.52%
FREE CASH FLOW
Cash From Operating Activities	$4.921M	-$12.44M
Capital Expenditures	$19.00K	$676.0K
Free Cash Flow	$4.902M	-$13.11M
YoY Change	-137.39%	-669.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14835438	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	EAGLE PHARMACEUTICALS, INC.
CY2017Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	2657000	USD
CY2017Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	936000	USD
CY2017Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	2389000	USD
CY2018Q1	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	724000	USD
CY2017Q3	egrx	Clinical Development Cost Sharing Percentage ClinicalDevelopmentCostSharingPercentage	0.5
CY2017Q4	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	7235000	USD
CY2018Q1	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	7235000	USD
CY2017Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-3252000	USD
CY2018Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-1518000	USD
CY2017Q1	egrx	Interest Expense Noncash InterestExpenseNoncash	27000	USD
CY2018Q1	egrx	Interest Expense Noncash InterestExpenseNoncash	0	USD
CY2017Q4	egrx	Number Of Clinical Trial Sites NumberOfClinicalTrialSites	12	site
CY2018Q1	egrx	License Agreement Potential Milestone Payments LicenseAgreementPotentialMilestonePayments	10000000	USD
CY2017Q3	egrx	License Agreement Proceeds From Upfront Payment LicenseAgreementProceedsFromUpfrontPayment	12500000	USD
CY2018Q1	egrx	Number Of Products NumberOfProducts	4	product
CY2018Q1	egrx	Obligations Future Payments ObligationsFuturePayments	131445000	USD
CY2018Q1	egrx	Obligations Future Payments Due In Fifth Year ObligationsFuturePaymentsDueInFifthYear	120000	USD
CY2018Q1	egrx	Obligations Future Payments Due In Fourth Year ObligationsFuturePaymentsDueInFourthYear	117000	USD
CY2018Q1	egrx	Obligations Future Payments Due In Second Year ObligationsFuturePaymentsDueInSecondYear	5674000	USD
CY2018Q1	egrx	Obligations Future Payments Due In Third Year ObligationsFuturePaymentsDueInThirdYear	39145000	USD
CY2018Q1	egrx	Obligations Future Payments Due Next Twelve Months ObligationsFuturePaymentsDueNextTwelveMonths	85871000	USD
CY2018Q1	egrx	Obligations Future Payments Due Thereafter ObligationsFuturePaymentsDueThereafter	518000	USD
CY2017Q1	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	0	USD
CY2018Q1	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	15001000	USD
CY2017Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1369000	USD
CY2018Q1	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	912000	USD
CY2017Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	1069000	USD
CY2018Q1	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	0	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11981000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9353000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53821000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53426000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15391000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13102000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1254000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4310000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4811000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	233639000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	237059000	USD
CY2018Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3051000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5305000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4193000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5305000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	94000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	712000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	670000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1522317	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1985879	shares
CY2017Q4	us-gaap	Assets Assets	270060000	USD
CY2018Q1	us-gaap	Assets Assets	249296000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	188697000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	168820000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	426000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	27000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	15055000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	55000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	709000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	735000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52820000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27710000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114657000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95670000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25110000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18987000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16089439	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16166259	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10765000	USD
CY2018Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	7223000	USD
CY2018Q1	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	900000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	11354000	USD
CY2018Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	11477000	USD
CY2017Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	4212000	USD
CY2018Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-123000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	196000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	341000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.50
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.18
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.42
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.17
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.30
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.58
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3763000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4433000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	10336000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2010000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1651000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2905000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2948000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2802000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34320000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34320000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23322000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22652000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	39743000	USD
CY2017Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	32672000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1657000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9748000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-959000	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2018Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	96000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4311000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2628000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42548000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-395000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-9838000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2289000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	276000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1023000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	27000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-18000	USD
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	907469	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	658805	shares
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23322000	USD
CY2018Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22652000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	27000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	675000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	0	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	368000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1698000	USD
CY2018Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1451000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	5118000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	6141000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2489000	USD
CY2018Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3758000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	931000	USD
CY2018Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	932000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	27000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	162000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	153000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	270060000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	249296000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47302000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	28760000	USD
CY2017Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1700000	USD
CY2018Q1	us-gaap	Long Term Debt LongTermDebt	48750000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4875000	USD
CY2018Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	6250000	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	5000000	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	38750000	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5000000	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	5000000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	42905000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	41624000	USD
CY2017Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	5936000	USD
CY2018Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	895000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11998000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-23889000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-676000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12436000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4921000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	22924000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	2616000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	22924000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2616000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-648000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	44097000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	44321000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	32696000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2305000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2326000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	502000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	120000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	117000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	395000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	674000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	518000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1423000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	561000	USD
CY2018Q1	us-gaap	Other Assets Current OtherAssetsCurrent	580000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	124000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	106000	USD
CY2018Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7003000	USD
CY2017Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	482000	USD
CY2017Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	25000000	USD
CY2018Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13653000	USD
CY2018Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3051000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	676000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15101000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13583000	USD
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	116000	USD
CY2018Q1	us-gaap	Prepaid Insurance PrepaidInsurance	843000	USD
CY2017Q4	us-gaap	Prepaid Taxes PrepaidTaxes	9597000	USD
CY2018Q1	us-gaap	Prepaid Taxes PrepaidTaxes	10524000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2137000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1166000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6820000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6498000	USD
CY2018Q1	us-gaap	Purchase Obligation PurchaseObligation	80369000	USD
CY2018Q1	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2018Q1	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2018Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2018Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	80369000	USD
CY2018Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2018Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7525000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17320000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	26284000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	28900000	USD
CY2017Q1	us-gaap	Royalty Expense RoyaltyExpense	7229000	USD
CY2018Q1	us-gaap	Royalty Expense RoyaltyExpense	4585000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	36507000	USD
CY2018Q1	us-gaap	Royalty Revenue RoyaltyRevenue	35788000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15286000	USD
CY2018Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10838000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	76793000	USD
CY2018Q1	us-gaap	Sales Revenue Net SalesRevenueNet	46626000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18578000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15193000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4193000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5305000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3727
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4376
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0242
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0271
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0191
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0230
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	810650	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	631625	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	33.56
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	26.58
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	84.92
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	59.14
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1166000	USD
CY2016Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	75000000.0	USD
CY2017Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	100000000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	179144000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	178177000	USD
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1241695	shares
CY2018Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1365386	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1365386	shares
CY2018Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	123691	shares
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	80795000	USD
CY2018Q1	us-gaap	Treasury Stock Value TreasuryStockValue	87798000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	87800000	USD
CY2018Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	7003000	USD
CY2018Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	7000000	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	16165361	shares
CY2018Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15478335	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16165361	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15478335	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15257892	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14819530	shares
CY2018Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2017 was derived from audited financial statements, but certain information and footnote disclosures normally included in the Company's annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on February 26, 2018. Unless otherwise indicated or required by context, reference throughout to the "Company," "Eagle Pharmaceuticals," "Eagle," "we," "us" or "our" mean Eagle Pharmaceuticals, Inc., a Delaware corporation and its subsidiary, Eagle Biologics, Inc., and references to "Eagle Biologics" mean Eagle Biologics, Inc.</font></div></div>
CY2018Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000827871-18-000005-index-headers.html	Edgar Link	pending
0000827871-18-000005-index.html	Edgar Link	pending
0000827871-18-000005.txt	Edgar Link	pending
0000827871-18-000005-xbrl.zip	Edgar Link	pending
egrx-20180331.xml	Edgar Link	completed
egrx-20180331.xsd	Edgar Link	pending
egrx-20180331_cal.xml	Edgar Link	unprocessable
egrx-20180331_def.xml	Edgar Link	unprocessable
egrx-20180331_lab.xml	Edgar Link	unprocessable
egrx-20180331_pre.xml	Edgar Link	unprocessable
egrx_q1x2018.htm	Edgar Link	pending
exhibit104q12018.htm	Edgar Link	pending
exhibit311q12018.htm	Edgar Link	pending
exhibit312q12018.htm	Edgar Link	pending
exhibit321q12018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2018 Q1 Form 10-Q Financial Statement

#000082787118000005 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2018 Q1 Form 10-Q Financial Statement

#000082787118000005 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx